ABSTRACT
BACKGROUND: Secukinumab is a first-in-class interleukin 17A monoclonal antibody that has demonstrated an excellent safety and efficacy profile in phase 3 studies. OBJECTIVE: To evaluate the effectiveness of secukinumab in daily clinical practice and to understand the clinical and epidemiologic characteristics of patients treated with secukinumab in clinical settings. METHODS: In this multicenter prospective observational study, we recruited adult patients with moderate-to-severe plaque psoriasis from 12 hospitals in Spain during January-December 2016. These patients were treated with secukinumab and prospectively followed at 12-week intervals for 52 weeks. RESULTS: In total, 158 patients were recruited to the study. A Psoriasis Area and Severity Index (PASI) score improvement ≥75% over baseline (PASI-75) was achieved by 57%, 83.5%, 89%, and 78.5% of patients at weeks 4, 12, 24, and 52, respectively. PASI-90 was achieved in 27.8%, 62%, 64.6%, and 63.2% of patients at weeks 4, 12, 24, and 52, respectively; PASI-75 and PASI-90 responders were significantly more common among patients with a body mass index <30 kg/cm2 and patients without previous biologic therapy failures. LIMITATIONS: Observational study. Time from onset of psoriasis was not evaluated. CONCLUSION: Secukinumab is a safe treatment with effectiveness rates similar to those found in its phase 3 studies. These rates endure up to a year from start of treatment.
Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Dermatologic Agents/therapeutic use , Psoriasis/drug therapy , Adult , Antibodies, Monoclonal, Humanized/adverse effects , Body Mass Index , Dermatologic Agents/adverse effects , Female , Humans , Male , Middle Aged , Prospective Studies , Severity of Illness Index , Treatment OutcomeABSTRACT
Actinic cheilitis (AC) are premalignant lesions that have an increased risk of malignant transformation. Their treatment, therefore, is essential to prevent carcinogenesis. However, optimal therapy is not well established and different modalities yield variable results. Ingenol mebutate gel has recently been approved by the US Food and Drug Administration for topical treatment of actinic keratosis, with high clearance rates. On the basis of these findings, we report our experience with this drug for the treatment of AC.
Subject(s)
Antineoplastic Agents/administration & dosage , Cheilitis/drug therapy , Diterpenes/administration & dosage , Lip Neoplasms/drug therapy , Lip/drug effects , Precancerous Conditions/drug therapy , Administration, Topical , Aged , Cheilitis/diagnosis , Gels , Humans , Lip/pathology , Lip Neoplasms/diagnosis , Male , Precancerous Conditions/diagnosis , Remission Induction , Time Factors , Treatment OutcomeABSTRACT
No disponible